- Home
- BHC vs GHRS Comparison
BHC vs GHRS Comparison
Compare BHC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BHC | GHRS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BHC | GHRS |
|---|---|---|
| Price | $6.21 | $30.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $8.00 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 4.8M | 328.9K |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 423.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,724,000,000.00 | N/A |
| Revenue This Year | $4.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.33 | $11.83 |
| 52 Week High | $8.69 | $31.44 |
Technical Indicators
Market Signals| Indicator | BHC | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 61.68 |
| Support Level | $5.42 | $25.66 |
| Resistance Level | $7.34 | $31.00 |
| Average True Range (ATR) | 0.44 | 1.43 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 63.32 | 71.39 |
Price Performance
Historical ComparisonAbout BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.